28
Participants
Start Date
December 31, 2011
Primary Completion Date
August 31, 2013
Study Completion Date
September 30, 2013
tivantinib
three oral 120 mg tablets administered twice a day
omeprazole
One 40 mg oral capsule once alone and once again with tivantinib
s-warfarin
One 10 mg oral tablet once alone and once again with tivantinib
caffeine
One 200 mg oral tablet once alone and once again with tivantinib
vitamin K
One oral 5 mg tablet on multiple days when and around warfarin administration
digoxin
One oral 0.25 mg tablet once alone and once again with tivantinib
midazolam
Intravenous 1.5 mg dose once alone and once again with tivantinib
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Daiichi Sankyo
INDUSTRY